Interpace Biosciences, Inc.
A molecular diagnostics company that helps doctors tell whether a suspicious thyroid nodule is cancerous, so patients can avoid needless surgery. Its lab tests, ThyGeNEXT® and ThyraMIR®, read DNA, RNA and microRNA to gauge the risk of malignancy. The business began in 2014 as the diagnostic arm of PDI, a pharmaceutical sales-services firm, and became its own company in 2015. The name "Interpace" plays on "interface," reflecting its role as a bridge between diagnosis and treatment.
Granted 767.4K · Bought 116.0K
Bought 83.3K
Granted 202.0K · Bought 258.6K
Granted 225.0K · Bought 10.9K
Granted 189.9K · Bought 22.0K
Granted 108.1K · Bought 79.7K
Granted 137.8K · Bought 5.0K · Sold 6.8K
Granted 127.7K
Granted 26.3K · Bought 2.5K
Granted 87.4K · Bought 3.0K
Granted 52.0K
Granted 73.5K
Granted 40.1K
Granted 21.2K · Bought 15.0K
Granted 27.7K · Bought 6.0K
Granted 25.1K
Granted 428.9K
Granted 8.0K
Granted 23.3K
Granted 196.6K
Granted 17.0K
Granted 32.0K
Granted 18.8K
Granted 132.5K
Granted 50.2K
Granted 15.5K
Granted 19.9K
Granted 21.5K
Granted 29.0K
Granted 10.0K · Sold 10.0K
Granted 10.1K
Granted 82.9K
Granted 48.3K
Granted 5.2K
Granted 4.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ampersand 2018 Limited Partnership10% owner · 1 transaction | — | 13.86M | — | — | — |
| 1315 Capital II, L.P.10% owner · 1 transaction | — | 9.41M | — | — | — |
| Lurker NancyCEO, Director · 20 transactions | — | 2.36Mas of Mar 2015 | 767.4K | 116.0K | — |
| Kamin Peter10% owner · 8 transactions | — | 1.52Mas of Mar 2021 | — | 83.3K | — |
| Smith Jeffrey EdwardVP of Corporate Development · 18 transactions | — | 267.2Kas of Nov 2014 | 202.0K | 258.6K | — |
| Burnell Thomas W.President & CEO, Director · 3 transactions | — | 235.9Kas of May 2021 | 225.0K | 10.9K | — |
| Miao Graham GCFO · 5 transactions | — | 211.9Kas of Dec 2015 | 189.9K | 22.0K | — |
| Belle Gerald P.Director · 12 transactions | — | 154.9Kas of Jun 2015 | 108.1K | 79.7K | — |
| Melillo Gerald R JRPresident, Sales Services · 10 transactions | — | 136.9Kas of Dec 2015 | 137.8K | 5.0K | 6.8K |
| Glorikian HarryDirector · 1 transaction | — | 127.7Kas of Feb 2016 | 127.7K | — | — |
| Marquard MichaelCEO · 4 transactions | — | 69.8Kas of Jun 2008 | 26.3K | 2.5K | — |
| Federspiel JohnDirector · 17 transactions | — | 66.3Kas of Jun 2015 | 87.4K | 3.0K | — |
| Saitta Jo AnnSVP and CIO, GM GROUP DCA · 3 transactions | — | 57.2Kas of Mar 2013 | — | — | — |
| Freeburg Thomas JohnChief Financial Officer · 2 transactions | — | 52.0Kas of Mar 2021 | 52.0K | — | — |
| McCarthy ChristopherChief Financial Officer · 8 transactions | — | 46.8Kas of Dec 2024 | 73.5K | — | — |
| Lubatkin VeronicaDirector · 5 transactions | — | 44.1Kas of Jun 2013 | 40.1K | — | — |
| Vecsi Jan MartensDirector · 13 transactions | — | 41.1Kas of Jun 2010 | 21.2K | 15.0K | — |
| Ryan Frank JDirector · 6 transactions | — | 37.2Kas of Jun 2011 | 27.7K | 6.0K | — |
| Connolly KevinEVP, Marketing Services · 3 transactions | — | 32.4Kas of Jun 2008 | 25.1K | — | — |
| Stover Jack EPresident and CEO, Director · 14 transactions | — | 30.3Kas of Mar 2020 | 428.9K | — | — |
| Drazner HowardSVP,Bus. Dev Medical Education · 5 transactions | — | 26.9Kas of Dec 2010 | 8.0K | — | — |
| Budd Steven KPresident · 2 transactions | — | 26.0Kas of Aug 2006 | 23.3K | — | — |
| Sullivan Stephen JDirector · 11 transactions | — | 24.6Kas of Mar 2018 | 196.6K | — | — |
| McCarthy NancyEVP, Human Resources · 3 transactions | — | 20.5Kas of Jun 2008 | 17.0K | — | — |
| Micali Richard PSenior VP, Sales Services · 4 transactions | — | 19.0Kas of Mar 2011 | 32.0K | — | — |
| Gorman Robert J.Director · 2 transactions | — | 18.8Kas of Jan 2021 | 18.8K | — | — |
| Keegan Joseph DDirector · 2 transactions | — | 17.6Kas of Mar 2018 | 132.5K | — | — |
| Dreismann HeinerDirector · 2 transactions | — | 16.1Kas of Jun 2015 | 50.2K | — | — |
| Pietruski John MDirector · 3 transactions | — | 15.2Kas of Jun 2009 | 15.5K | — | — |
| Curti Joseph IDirector · 3 transactions | — | 13.2Kas of Jun 2009 | 19.9K | — | — |
| Climaco John MDirector · 2 transactions | — | 11.6Kas of Jun 2014 | 21.5K | — | — |
| Kerr David ESenior VP Business Development · 4 transactions | — | 11.0Kas of Mar 2011 | 29.0K | — | — |
| Jacobson BethFormer Exec VP & GC · 2 transactions | — | 10.0Kas of Mar 2006 | 10.0K | — | 10.0K |
| Cotugno StephenExecutive Vice-President · 2 transactions | — | 9.2Kas of Aug 2006 | 10.1K | — | — |
| Richard GregoryChief Commerical Officer · 4 transactions | — | 8.5Kas of Feb 2020 | 82.9K | — | — |
| Early JamesFormer Chief Financial Officer · 4 transactions | — | 7.1Kas of Jul 2020 | 48.3K | — | — |
| Farrell James G.VP, Corporate Controller · 2 transactions | — | 5.2Kas of Nov 2008 | 5.2K | — | — |
| Schnoll-Sussman FeliceDirector · 1 transaction | — | 4.8Kas of Mar 2018 | 4.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +585.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.